Using Gene Editing Approaches to Fine-Tune the Immune System
| Autor: | Pavlovic, Kristina, Tristán-Manzano, María, Maldonado-Pérez, Noelia, Cortijo-Gutierrez, Marina, Sánchez-Hernández, Sabina, Justicia-Lirio, Pedro, Carmona, M. Dolores, Herrera, Concha, Martin, Francisco, Benabdellah, Karim |
|---|---|
| Přispěvatelé: | [Pavlovic,K, Tristán-Manzano,M, Maldonado-Pérez,N, Cortijo-Gutierrez,M, Sánchez-Hernández,S, Justicia-Lirio,P, Martin,F, Benabdellah,K] Genomic Medicine Department, GENYO, Centre for Genomics and Oncological Research, Pfizer-University of Granada (Andalusian Regional Government), Health Sciences Technology Park, Granada, Spain. [Pavlovic,K, Carmona,MD, Herrera,C] Maimonides Institute of Biomedical Research in Cordoba (IMIBIC), Cellular Therapy Unit, Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, [Justicia-Lirio,P] LentiStem Biotech, GENYO, Centre for Genomics and Oncological Research, Pfizer-University of Granada (Andalusian Regional Government), Health Sciences Technology Park, Granada, Spain. [Herrera,C] Department of Hematology, Reina Sofía University Hospital, Córdoba, Spain, This study was funded by the Spanish ISCIII Health Research Fund and the European Regional Development Fund (FEDER) through research grants PI12/01097, PI15/02015, PI18/00337 (FM), and PI18/00330 (KB) The CECEyU and CSyF councils of the Junta de Andalucía FEDER/European Cohesion Fund (FSE) for Andalusia provided the following research grants: 2016000073391-TRA, 2016000073332-TRA, PI-57069, and PAIDI-Bio326 (FM) and PI-0014-2016 (KB). KB was also on a Nicolas Monardes regional Ministry of Health contract (0006/2018). MT-M and NM-P are funded by the Spanish Ministry of Science and Innovation (SMSI) through fellowships FPU16/05467 and FPU17/02268, respectively. PJ-L is funded by Industrial Doctorate Plan MCI DIN2018-010180 with LentiStem Biotech. MC-G is funded by SMSI by a GJ fellowship (PEJ-2018-001760-A). |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Chemicals and Drugs::Amino Acids
Peptides and Proteins::Proteins::CRISPR-Associated Proteins [Medical Subject Headings] Base editors Edición génica Chemicals and Drugs::Complex Mixtures::Biological Products::Vaccines::Cancer Vaccines [Medical Subject Headings] Gene editing Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization Passive::Adoptive Transfer::Immunotherapy Adoptive [Medical Subject Headings] Diseases::Neoplasms [Medical Subject Headings] Enfermedad injerto contra huésped Receptores quiméricos de antígenos Zinc Finger Nucleases Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression Regulation::Epigenesis Genetic::Gene Silencing::CRISPR-Cas Systems [Medical Subject Headings] Diseases::Immune System Diseases::Graft vs Host Disease [Medical Subject Headings] Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] Sistema inmunológico Graft-vs-host disease Organisms::Eukaryota::Animals [Medical Subject Headings] CARs Phenomena and Processes::Immune System Phenomena::Immune System Processes::Transplantation Immunology::Host vs Graft Reaction::Graft Rejection [Medical Subject Headings] Immunotherapy Inmunoterapia Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Genetic Engineering::Genetic Therapy [Medical Subject Headings] |
| Popis: | Genome editing technologies not only provide unprecedented opportunities to study basic cellular system functionality but also improve the outcomes of several clinical applications. In this review, we analyze various gene editing techniques used to fine-tune immune systems from a basic research and clinical perspective. We discuss recent advances in the development of programmable nucleases, such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)-Cas-associated nucleases. We also discuss the use of programmable nucleases and their derivative reagents such as base editing tools to engineer immune cells via gene disruption, insertion, and rewriting of T cells and other immune components, such natural killers (NKs) and hematopoietic stem and progenitor cells (HSPCs). In addition, with regard to chimeric antigen receptors (CARs), we describe how different gene editing tools enable healthy donor cells to be used in CAR T therapy instead of autologous cells without risking graft-versus-host disease or rejection, leading to reduced adoptive cell therapy costs and instant treatment availability for patients. We pay particular attention to the delivery of therapeutic transgenes, such as CARs, to endogenous loci which prevents collateral damage and increases therapeutic effectiveness. Finally, we review creative innovations, including immune system repurposing, that facilitate safe and efficient genome surgery within the framework of clinical cancer immunotherapies. Yes |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|